MK-677

In a year-long placebo-controlled trial of healthy adults aged 60 to 81, daily oral MK-677 lifted growth hormone and IGF-1 to the levels of healthy young adults and added 1.1 kg of fat-free mass while the placebo group lost 0.5 kg. In the same participants, strength and physical function did not change. That pairing is the core of the compound: a hormone signal that moves every time, and outcomes that mostly stay where they were.

MK-677, also known as ibutamoren mesylate, is not a peptide. It is a non-peptidyl molecule taken as a tablet that binds the ghrelin receptor, and it sits beside injectable peptides because of where it is sold, not what it is. Two trials in older patients recovering from hip fracture pushed IGF-1 up hard and still found no improvement in most functional measures. The second was terminated early over a congestive heart failure signal, and that trial is the one FDA points to when it lists ibutamoren mesylate in category 2 under both compounding policies.

FDA has never approved it, and the World Anti-Doping Agency names it on the Prohibited List at all times.

Ibutamoren mesylate came out of Merck's medicinal chemistry department, which published its design in 1995 under the codes L-163,191 and MK-0677 and described it as a potent, orally active growth hormone secretagogue. The 2011 hip-fracture trial calls it an orally available non-peptidyl mimetic that binds the ghrelin receptor and stimulates growth hormone secretion.

Put simply, it is a ghrelin mimetic. It occupies the receptor ghrelin uses and prompts the pituitary to release more of its own growth hormone. It supplies no hormone itself.

The peptide label is a retail habit rather than chemistry. Being a non-peptide built to work by mouth is the property that separates it from the injectable secretagogues it is usually compared with, and it is why its regulatory and anti-doping listings name it on its own terms.

Prompting the Pituitary Instead of Replacing It

Growth hormone output and muscle mass both decline from midpuberty onward, and that parallel is what made secretagogues worth building. Injected growth hormone replaces the hormone from outside. A secretagogue works one step upstream and asks the pituitary for more of its own.

A 1996 placebo-controlled study in 32 healthy adults aged 64 to 81 showed what that looks like. After two weeks at the highest dose tested, mean 24-hour growth hormone was up 97 percent, and the rise came from taller pulses and higher troughs rather than more pulses. The existing rhythm was amplified, not flattened. By four weeks, IGF-1 had climbed from 141 to 265 micrograms per litre, into the normal range for young adults.

Two Steps Between Receptor and Result

Receptor binding drives growth hormone release, and growth hormone drives IGF-1. IGF-1 in turn feeds back to restrain growth hormone, which the 2008 trial authors give as the likely reason levels rose into the young-adult range without running to excess. When participants crossed over to placebo, IGF-1 was back at pretreatment levels a month later.

Every link in that chain is a hormone measurement. None of it measures what a muscle can do, and the trials that did measure that are the ones that settle what the compound is worth.

The overreach with MK-677 runs one way: from a hormone number to a change in the body someone can feel.

A higher IGF-1 is not added strength. The compound raised IGF-1 in every trial, by 84 percent in one and by 51.4 ng/ml over placebo in another. Strength and function did not move in healthy older adults, and across the two hip-fracture trials gait speed in the later one was the only functional measure to separate from placebo. Reading a lab value as a performance result is the inference these trials existed to check.

Fat-free mass is not the same as usable muscle. The 1.1 kg gain was real, and the authors attribute it mainly to a rise in intracellular water, a marker of body cell mass. Limb fat also rose more on the compound than on placebo, 1.1 kg against 0.24 kg. Not all of the weight gained was lean tissue.

Older trial participants are not young lifters. Every outcome trial enrolled older adults, two of them in people recovering from hip fracture, and the longest exposure was two years. None of the trials enrolled younger or trained people, so nothing in the record speaks to them.

The adverse findings fall into three groups, and the cardiac one is why the compound holds its regulatory status.

Heart failure. The 2011 hip-fracture trial was terminated early after a congestive heart failure signal in what its abstract calls a limited number of patients, and its authors conclude MK-677 has an unfavourable safety profile in that population. FDA cites that trial in stating that ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients. Neither source gives an event rate. Separately, in the healthy-adult trial a 68-year-old woman had a myocardial infarction seven days after starting the compound and was withdrawn.

Glucose control. Over 12 months in healthy adults, fasting glucose rose 0.3 mmol/L (5 mg/dL) on MK-677 and did not change on placebo (P=0.015). HbA1c rose 0.2 points against a 0.1 point fall (P=0.002), and insulin sensitivity declined. Sixteen people on the compound moved from normal fasting glucose into the 5.6 to 6.1 mmol/L band, against two on placebo. The 1996 study had already recorded fasting glucose climbing from 5.4 to 6.8 mmol/L within four weeks. Cortisol rose too, by 47 nmol/L.

Everyday effects and bone. Increased appetite was reported by 67 percent on the compound against 36 percent on placebo, and returned to normal within three months in half of those treated. Mild, transient leg swelling (44 against 27 percent) and transient muscle pain (33 against 9 percent) were more common on MK-677 without reaching significance. At 12 months femoral neck bone density had fallen slightly on the compound while rising slightly on placebo, a difference of 0.018 g/cm2 (P=0.004) that the authors read as increased bone remodelling.

Here is what the evidence supports firmly. Daily oral MK-677 raises growth hormone and IGF-1 in older adults, keeps the pulsed release pattern, and adds roughly a kilogram of fat-free mass over a year in healthy people aged 60 to 81.

Here is what it does not support. There is no trial showing better strength, function, recovery or athletic performance. Three trials looked at function, and gait speed in one of them was the single measure that moved. There is also nothing on people under 60 or on exposure beyond two years.

The harms are better documented than the benefits: a heart failure signal serious enough to stop a trial, measurable loss of glucose control in healthy volunteers, and lower femoral neck bone density at one year. Set against those is a gain in fat-free mass that did not change what participants could physically do. That is the trade the trials actually describe.

Not a peptide. It is an orally available non-peptidyl molecule that binds the ghrelin receptor. It shares a sales channel with injectable growth hormone peptides, not a chemical class.

Not an approved medicine. FDA has not approved ibutamoren mesylate, and lists it in category 2 under the 503B policy since 29 December 2022 and the 503A policy since 29 September 2023. Category 2 records a published safety concern about compounding with the substance. It is not a scheduling action.

Not permitted in tested sport. WADA names ibutamoren (MK-677) at S2.2.4 among growth hormone secretagogues and their mimetics. It is prohibited at all times, in and out of competition, as a non-specified substance.

Not a strength compound. The fat-free mass gain in healthy older adults came without any change in strength or function, and two hip-fracture trials found no improvement in most functional measures despite large IGF-1 rises.

MK-677 is the clearest case I know of a marker and an outcome parting ways inside the same group of people. The hormone response is about as reliable as these things get. The trials still could not find the strength, function or recovery that the hormone response is supposed to deliver.

That matters beyond this one compound. When all anyone has is marker data, it is tempting to assume the outcome will follow. Here somebody ran the outcome trials, with placebo arms, in the people most likely to benefit, and the answer came back mostly no, with a heart failure signal attached.

I am not going to tell anyone what to do with that. I will say where I land. I take FDA's stated concern at face value, I do not treat an IGF-1 result as evidence of anything beyond itself, and a kilogram of fat-free mass that changed nothing participants could do is not a result I would trade glucose control for.